Erratum: Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners (The Lancet (2016) 388(10049) (1115–1126) (S0140673616307693) (10.1016/S0140-6736(16)30769-3));Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners

The Lancet

Volumn 388, Issue 10049, 2016, Pages 1115-1126

  Kamarulzaman, Adeeba ^a,b   Reid, Stewart E ^c,d   Schwitters, Amee ^e   Wiessing, Lucas ^f   El Bassel, Nabila ^g   Dolan, Kate ^h   Moazen, Babak ^i,j   Wirtz, Andrea L ^k   Verster, Annette ^e   Altice, Frederick L ^a,b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; OPIATE;

ANTIVIRAL THERAPY; BLOODSTREAM INFECTION; DISEASE TRANSMISSION; HEALTH CARE PLANNING; HEALTH EDUCATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INFORMATION DISSEMINATION; PREVENTION STUDY; PRIORITY JOURNAL; PRISONER; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; TUBERCULOSIS; VACCINATION; HIV INFECTIONS; PRIMARY PREVENTION; STATISTICS AND NUMERICAL DATA; TRANSMISSION;

HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; PRIMARY PREVENTION; PRISONERS; SECONDARY PREVENTION; TUBERCULOSIS;

EID: 84986247449     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31346-6     Document Type: Erratum

References (103)

1. 1 Dolan, K, Wirtz, AL, Moazen, B, et al. HIV and related infections in prisoners 1. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet, 2016 published online July 14. http://dx.doi.org/10.1016/S0140-6736(16)30466-4.
2. 2 UNAIDS. The Gap Report, 2014, UNAIDS, Geneva.
3. 3 Jurgens, R, Nowak, M, Day, M, HIV and incarceration: prisons and detention. J Int AIDS Soc, 14, 2011, 26.
4. 4 Ginn, S, Prison environment and health. BMJ, 345, 2012, e5921.
5. 5 Rhodes, T, The ‘risk environment’: a framework for understanding and reducing drug-related harm. Int J Drug Policy 13 (2002), 85–94.
6. 6 Maru, DS, Basu, S, Altice, FL, HIV control efforts should directly address incarceration. Lancet Infect Dis 7 (2007), 568–569.
7. 7 Fazel, S, Baillargeon, J, The health of prisoners. Lancet 377 (2011), 956–965.
8. 8 Awofeso, N, Prisons as social determinants of hepatitis C virus and tuberculosis infections. Public Health Rep 1250:suppl 4 (2010), 25–33.
9. 9 WHO UN Office on Drugs and Crime, Joint United Nations Programme on HIV/AIDS. HIV prevention, treatment and care in prisons and other closed settings: a comprehensive package of interventions. https://www.unodc.org/documents/hiv-aids/HIV_comprehensive_package_prison_2013_eBook.pdf, 2013 (accessed Oct 20, 2015).
10. 10 WHO Regional Office for Europe. Prisons and health. http://www.euro.who.int/__data/assets/pdf_file/0005/249188/Prisons-and-Health.pdf, 2014 (accessed Oct 27, 2015).
11. 11 Underhill, K, Dumont, D, Operario, D, HIV prevention for adults with criminal justice involvement: a systematic review of HIV risk-reduction interventions in incarceration and community settings. Am J Public Health 104 (2014), e27–e53.
12. 12 Gough, E, Kempf, MC, Graham, L, et al. HIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis. BMC Public Health, 10, 2010, 777.
13. 13 Dumont, DM, Brockmann, B, Dickman, S, Alexander, N, Rich, JD, Public health and the epidemic of incarceration. Annu Rev Public Health 33 (2012), 325–339.
14. 14 Culbert, GJ, Waluyo, A, Iriyanti, M, Muchransyah, AP, Kamarulzaman, A, Altice, FL, Within-prison drug injection among HIV-infected male prisoners in Indonesia: a highly constrained choice. Drug Alcohol Depend 149 (2015), 71–79.
15. 15 Bird, SM, Prevalence of drug injecting among prison inmates. Commun Dis Public Health 3 (2000), 308–309.
16. 16 Boys, A, Farrell, M, Bebbington, P, et al. Drug use and initiation in prison: results from a national prison survey in England and Wales. Addiction 97 (2002), 1551–1560.
17. 17 Azbel, L, Polonsky, M, Wegman, M, et al. Intersecting epidemics of HIV, HCV, and syphilis among soon-to-be released prisoners in Kyrgyzstan: implications for prevention and treatment. Int J Drug Policy, 2016, 10.1016/j.drugpo.2016.06.007 published online June 11.
18. 18 Dolan, K, Moazen, B, Noori, A, Rahimzadeh, S, Farzadfar, F, Hariga, F, People who inject drugs in prison: HIV prevalence, transmission and prevention. Int J Drug Policy 26:suppl 1 (2015), S12–S15.
19. 19 Jürgens, R, Ball, A, Verster, A, Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis 9 (2009), 57–66.
20. 20 Zamani, S, Farnia, M, Torknejad, A, et al. Patterns of drug use and HIV-related risk behaviors among incarcerated people in a prison in Iran. J Urban Health 87 (2010), 603–616.
21. 21 Izenberg, JM, Bachireddy, C, Wickersham, JA, et al. Within-prison drug injection among HIV-infected Ukrainian prisoners: prevalence and correlates of an extremely high-risk behaviour. Int J Drug Policy 25 (2014), 845–852.
22. 22 Pollini, RA, Alvelais, J, Gallardo, M, et al. The harm inside: injection during incarceration among male injection drug users in Tijuana, Mexico. Drug Alcohol Depend 103 (2009), 52–58.
23. 23 Kinner, SA, Jenkinson, R, Gouillou, M, Milloy, MJ, High-risk drug-use practices among a large sample of Australian prisoners. Drug Alcohol Depend 126 (2012), 156–160.
24. 24 Yang, S, Wang, D, Zhang, Y, et al. Transmission of hepatitis B and C virus infection through body piercing: a systematic review and meta-Analysis. Medicine (Baltimore), 94, 2015, e1893.
25. 25 Pena-Orellana, M, Hernandez-Viver, A, Caraballo-Correa, G, Albizu-Garcia, CE, Prevalence of HCV risk behaviors among prison inmates: tattooing and injection drug use. J Health Care Poor Underserved 22 (2011), 962–982.
26. 26 Binswanger, IA, Stern, MF, Deyo, RA, et al. Release from prison—a high risk of death for former inmates. N Engl J Med 356 (2007), 157–165.
27. 27 Milloy, MJ, Buxton, J, Wood, E, Li, K, Montaner, JS, Kerr, T, Elevated HIV risk behaviour among recently incarcerated injection drug users in a Canadian setting: a longitudinal analysis. BMC Public Health, 9, 2009, 156.
28. 28 Buavirat, A, Page-Shafer, K, van Griensven, GJ, et al. Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: case-control study. BMJ, 326, 2003, 308.
29. 29 Altice, FL, Azbel, L, El-Bassel, N, et al. HIV and related infections in prisoners 6. The perfect storm: incarceration and multilevel contributors to perpetuating HIV and tuberculosis in eastern Europe and central Asia. Lancet, 2016 published online July 14. http://dx.doi.org/10.1016/S0140-6736(16)30856-X.
30. 30 Binswanger, IA, Nowels, C, Corsi, KF, et al. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract, 7, 2012, 3.
31. 31 Calcaterra, SL, Beaty, B, Mueller, SR, Min, SJ, Binswanger, IA, The association between social stressors and drug use/hazardous drinking among former prison inmates. J Subst Abuse Treat 47 (2014), 41–49.
32. 32 Harawa, NT, Sweat, J, George, S, Sylla, M, Sex and condom use in a large jail unit for men who have sex with men (MSM) and male-to-female transgenders. J Health Care Poor Underserved 21 (2010), 1071–1087.
33. 33 Epperson, MW, El-Bassel, N, Chang, M, Gilbert, L, Examining the temporal relationship between criminal justice involvement and sexual risk behaviors among drug-involved men. J Urban Health 87 (2010), 324–336.
34. 34 Richters, J, Butler, T, Schneider, K, et al. Consensual sex between men and sexual violence in Australian prisons. Arch Sex Behav 41 (2012), 517–524.
35. 35 Allen, J, Beck, MB, Caspar, R, Krebs, C, Sexual victimization in prisons and jails reported by inmates, 2011–12: national inmate survey, 2011–12. http://www.bjs.gov/content/pub/pdf/svpjri1112.pdf, 2013 (accessed Nov 20, 2015).
36. 36 Wolff, N, Jing, S, Contextualization of physical and sexual assault in male prisons: incidents and their aftermath. J Correct Health Care 15 (2009), 58–77.
37. 37 Topp, SM, Moonga, CN, Mudenda, C, et al. Prison food provisions, family support and vulnerability to health risks in Zambia. Trop Med Int Health 20:suppl 1 (2015), 375–376.
38. 38 Binswanger, IA, Blatchford, PJ, Lindsay, RG, Stern, MF, Risk factors for all-cause, overdose and early deaths after release from prison in Washington state. Drug Alcohol Depend 117 (2011), 1–6.
39. 39 Binswanger, IA, Mueller, SR, Beaty, BL, Min, SJ, Corsi, KF, Gender and risk behaviors for HIV and sexually transmitted infections among recently released inmates: a prospective cohort study. AIDS Care 26 (2014), 872–881.
40. 40 Baussano, I, Williams, BG, Nunn, P, Beggiato, M, Fedeli, U, Scano, F, Tuberculosis incidence in prisons: a systematic review. PLoS Med, 7, 2010, e1000381.
41. 41 Dara, M, Acosta, CD, Melchers, NV, et al. Tuberculosis control in prisons: current situation and research gaps. Int J Infect Dis 32 (2015), 111–117.
42. 42 Al-Darraji, HA, Kamarulzaman, A, Altice, FL, Isoniazid preventive therapy in correctional facilities: a systematic review. Int J Tuberc Lung Dis 16 (2012), 871–879.
43. 43 Johnstone-Robertson, S, Lawn, SD, Welte, A, Bekker, LG, Wood, R, Tuberculosis in a South African prison—a transmission modelling analysis. S Afr Med J 101 (2011), 809–813.
44. 44 Stuckler, D, Basu, S, McKee, M, King, L, Mass incarceration can explain population increases in TB and multidrug-resistant TB in European and central Asian countries. Proc Natl Acad Sci USA 105 (2008), 13280–13285.
45. 45 Sacchi, FP, Praca, RM, Tatara, MB, et al. Prisons as reservoir for community transmission of tuberculosis, Brazil. Emerg Infect Dis 21 (2015), 452–455.
46. 46 Ferrer-Castro, V, Crespo-Leiro, MR, Garcia-Marcos, LS, et al. Evaluation of needle exchange program at Pereiro de Aguiar prison (Ourense, Spain): ten years of experience. Rev Esp Sanid Penit 14 (2012), 3–11.
47. 47 Rumble, C, Pevalin, DJ, O'Moore, E, Routine testing for blood-borne viruses in prisons: a systematic review. Eur J Public Health 25 (2016), 1078–1088.
48. 48 Hedrich, D, Alves, P, Farrell, M, Stover, H, Møller, L, Mayet, S, The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction 107 (2012), 501–517.
49. 49 Larney, S, Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review. Addiction 105 (2010), 216–223.
50. 50 Butler, T, Richters, J, Yap, L, Donovan, B, Condoms for prisoners: no evidence that they increase sex in prison, but they increase safe sex. Sex Transm Infect 89 (2013), 377–379.
51. 51 Fluhmann, P, Wassmer, M, Schwendimann, R, Structured information exchange on infectious diseases for prisoners. J Correct Health Care 18 (2012), 198–209.
52. 52 Bagnall, AM, South, J, Hulme, C, et al. A systematic review of the effectiveness and cost-effectiveness of peer education and peer support in prisons. BMC Public Health, 15, 2015, 290.
53. 53 Moller, LF, van den Bergh, BJ, Karymbaeva, S, Esenamanova, A, Muratalieva, R, Drug use in prisons in Kyrgyzstan: a study about the effect of health promotion among prisoners. Int J Prison Health 4 (2008), 124–133.
54. 54 Coats, JT, Dillon, JF, The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: a systematic review of the literature. Int J Drug Policy 26 (2015), 1050–1055.
55. 55 Wright, N, Bleakley, A, Butt, C, et al. Peer health promotion in prisons: a systematic review. Int J Prison Health 7 (2011), 37–51.
56. 56 Belenko, S, Hiller, M, Visher, C, et al. Policies and practices in the delivery of HIV services in correctional agencies and facilities: results from a multisite survey. J Correct Health Care 19 (2013), 293–310.
57. 57 Fonner, VA, Denison, J, Kennedy, CE, O'Reilly, K, Sweat, M, Voluntary counseling and testing (VCT) for changing HIV-related risk behavior in developing countries. Cochrane Database Syst Rev, 9, 2012 CD001224.
58. 58 Post, JJ, Arain, A, Lloyd, AR, Enhancing assessment and treatment of hepatitis C in the custodial setting. Clin Infect Dis 57:suppl 2 (2013), S70–S74.
59. 59 Harm Reduction International. The global state of harm reduction 2014. http://www.ihra.net/files/2015/02/16/GSHR2014.pdf, 2014 (accessed Nov 10, 2015).
60. 60 Simon, RE, Pearson, SD, Hur, C, Chung, RT, Tackling the hepatitis C cost problem: a test case for tomorrow's cures. Hepatology 62 (2015), 1334–1336.
61. 61 MacArthur, GJ, van Velzen, E, Palmateer, N, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy 25 (2014), 34–52.
62. 62 Stoove, M, Treloar, CJ, Maher, L, Tyrrell, H, Wallace, J, Salvaging a prison needle and syringe program trial in Australia requires leadership and respect for evidence. The Medical journal of Australia 203 (2015), 319–320.
63. 63 Hagan, H, Pouget, ER, Des Jarlais, DC, A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 204 (2011), 74–83.
64. 64 Wickersham, JA, Zahari, MM, Azar, MM, Kamarulzaman, A, Altice, FL, Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug Alcohol Depend 132 (2013), 378–382.
65. 65 Larney, S, Dolan, K, A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care?. Eur Addict Res 15 (2009), 107–112.
66. 66 Bachireddy, C, Bazazi, AR, Kavasery, R, Govindasamy, S, Kamarulzaman, A, Altice, FL, Attitudes toward opioid substitution therapy and pre-incarceration HIV transmission behaviors among HIV-infected prisoners in Malaysia: implications for secondary prevention. Drug Alcohol Depend 116 (2011), 151–157.
67. 67 Polonsky, M, Azbel, L, Wickersham, JA, et al. Challenges to implementing opioid substitution therapy in Ukrainian prisons: Personnel attitudes toward addiction, treatment, and people with HIV/AIDS. Drug Alcohol Depend 148 (2015), 47–55.
68. 68 Friedmann, PD, Hoskinson, R, Gordon, M, et al. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus 33 (2012), 9–18.
69. 69 Degenhardt, L, Larney, S, Kimber, J, et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction 109 (2014), 1306–1317.
70. 70 Weller, S, Davis, K, Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev, 1, 2002, Cd003255.
71. 71 Insight Start Study Group, Lundgren, JD, Babiker, AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373 (2015), 795–807.
72. 72 Cohen, MS, Chen, YQ, McCauley, M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365 (2011), 493–505.
73. 73 WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV, 2015, World Health Organization, Geneva.
74. 74 Milloy, MJ, Montaner, JS, Wood, E, Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention. Curr HIV/AIDS Rep 11 (2014), 308–316.
75. 75 Rey, D, Post-exposure prophylaxis for HIV infection. Expert Rev Anti Infect Ther 9 (2011), 431–442.
76. 76 Fonner, VA, Dalglish, SL, Kennedy, CE, et al. Effectiveness and safety of oral HIV pre-exposure prophylaxis (PrEP) for all populations: a systematic review and meta-analysis. AIDS, 2016, 10.1097/QAD.0000000000001145 published online May 5.
77. 77 Meyer, JP, Moghimi, Y, Marcus, R, Lim, JK, Litwin, AH, Altice, FL, Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic hepatitis C care continuum. Int J Drug Policy 26 (2015), 922–935.
78. 78 Health Service Executive. National hepatitis C strategy 2011–2014. http://www.hse.ie/eng/services/Publications/HealthProtection/HepCstrategy.pdf, 2011 (accessed Nov 11, 2015).
79. 79 Gupta, S, Altice, FL, Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implications. J Urban Health 86 (2009), 263–279.
80. 80 Jin, H, Tan, Z, Zhang, X, Wang, B, Zhao, Y, Liu, P, Comparison of accelerated and standard hepatitis B vaccination schedules in high-risk healthy adults: a meta-analysis of randomized controlled trials. PLoS One, 10, 2015, e0133464.
81. 81 Shah, DP, Grimes, CZ, Nguyen, AT, Lai, D, Hwang, LY, Long-term effectiveness of accelerated hepatitis B vaccination schedule in drug users. Am J Public Health 105 (2015), e36–e43.
82. 82 Beck, CR, Cloke, R, O'Moore, E, Puleston, R, Hepatitis B vaccination coverage and uptake in prisons across England and Wales 2003–2010: a retrospective ecological study. Vaccine 30 (2012), 1965–1971.
83. 83 WHO. Systematic screening for active tuberculosis: principles and recommendations. http://www.who.int/tb/publications/Final_TB_Screening_guidelines.pdf, 2013 (accessed Oct 25, 2015).
84. 84 Henostroza, G, Topp, SM, Hatwiinda, S, et al. The high burden of tuberculosis (TB) and human immunodeficiency virus (HIV) in a large Zambian prison: a public health alert. PLoS One, 8, 2013, e67338.
85. 85 Henostroza GJJ, Chitambi R, Syambango M, et al. High prevalence of tuberculosis in new HIV care enrollees in Lusaka Zambia: an enhanced screening approach. Int J Tuberc Lung Dis (in press).
86. 86 Reid, SE, Topp, SM, Turnbull, ER, et al. Tuberculosis and HIV control in sub-Saharan African prisons: “thinking outside the prison cell”. J Infect Dis 205:suppl 2 (2012), S265–S273.
87. 87 Urrego, J, Ko, AI, da Silva Santos Carbone, A, et al. The impact of ventilation and early diagnosis on tuberculosis transmission in Brazilian prisons. Am J Trop Med Hyg 93 (2015), 739–746.
88. 88 Maggard, KR, Hatwiinda, S, Harris, JB, et al. Screening for tuberculosis and testing for human immunodeficiency virus in Zambian prisons. Bull World Health Organ 93 (2015), 93–101.
89. 89 WHO. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. http://apps.who.int/iris/bitstream/10665/44472/1/9789241500708_eng.pdf, 2011 (accessed Oct 16, 2015).
90. 90 Lobato, MN, Leary, LS, Simone, PM, Treatment for latent TB in correctional facilities: a challenge for TB elimination. Am J Prev Med 24 (2003), 249–253.
91. 91 Sterling, TR, Villarino, ME, Borisov, AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 365 (2011), 2155–2166.
92. 92 Girardi, E, Sabin, CA, d'Arminio Monforte, A, et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 41 (2005), 1772–1782.
93. 93 Lawn, SD, Badri, M, Wood, R, Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 19 (2005), 2109–2116.
94. 94 Wood, R, Lawn, SD, Antiretroviral treatment as prevention: impact of the ‘test and treat’ strategy on the tuberculosis epidemic. Curr HIV Res 9 (2011), 383–392.
95. 95 UN Office on Drugs and Crime Joint United Nations Programme on HIV/AIDS, WHO. HIV testing and counselling in prisons and other closed settings. https://www.unodc.org/documents/hiv-aids/Final_UNODC_WHO_UNAIDS_technical_paper_2009_TC_prison_ebook.pdf, 2009 (accessed Nov 19, 2015).
96. 96 Michel, L, Lions, C, Van Malderen, S, et al. Insufficient access to harm reduction measures in prisons in 5 countries (PRIDE Europe): a shared European public health concern. BMC Public Health, 15, 2015, 1093.
97. 97 de la Fuente, L, Bravo, MJ, Jimenez-Mejias, E, Sordo, L, Pulido, J, Barrio, G, Evolution of the need and coverage of opioid substitution treatments and needle exchange programmes in Spanish prisons, 1992–2009. Rev Esp Sanid Penit 14 (2012), 67–77 (in Spanish).
98. 98 Zurhold, H, Stöver, H, Provision of harm reduction and drug treatment services in custodial settings—findings from the European ACCESS study. Drugs: Educ Prev Polic 23 (2015), 1–8.
99. 99 Todrys, KW, Amon, JJ, Criminal justice reform as HIV and TB prevention in African prisons. PLoS Med, 9, 2012, e1001215.
100. 100 Chandler, RK, Fletcher, BW, Volkow, ND, Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA 301 (2009), 183–190.
101. 101 Wickersham, JA, Marcus, R, Kamarulzaman, A, Zahari, MM, Altice, FL, Implementing methadone maintenance treatment in prisons in Malaysia. Bull World Health Organ 91 (2013), 124–129.
102. 102 Brewer, RA, Magnus, M, Kuo, I, Wang, L, Liu, TY, Mayer, KH, The high prevalence of incarceration history among Black men who have sex with men in the United States: associations and implications. Am J Public Health 104 (2014), 448–454.
103. 103 Rubenstein, LS, Amon, JJ, McLemore, M, et al. HIV and related infections in prisoners 4. HIV, prisoners, and human rights. Lancet, 2016 published online July 14. http://dx.doi.org/10.1016/S0140-6736(16)30663-8.